Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement, Equity-Method Investments and Cost-Method Investment - Medivation (Details) $ / shares in Units, $ in Millions			3 Months Ended
		Sep. 28, 2016 USD ($) oncology_assets $ / shares	Apr. 02, 2017 USD ($)	Apr. 03, 2016 USD ($)	Dec. 31, 2016 USD ($)
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 585	$ 110
Goodwill	[2]		54,656		$ 54,449
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares		$ 81.50
Payments for acquisitions, cash portion		$ 14,300
Cash payments for acquisition, net of cash acquired		$ 13,900
Number of development-stage oncology assets in progress | oncology_assets		2
Identifiable intangible assets		$ 13,100
Goodwill		5,500
Deferred tax liabilities		4,400
Contingent consideration assumed		340
Medivation [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		4,400
Medivation [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 8,700
Acquired intangible assets, average useful life		12 years
Other Current Liabilities [Member] | Medivation [Member]
Business Acquisition [Line Items]
Amount payable			$ 365

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.